Innovent and Daiichi Sankyo sign deal for Vanflyta in China
Innovent Biologics and Daiichi Sankyo have signed an exclusive agreement to commercialise Vanflyta, an oral type II FLT3 inhibitor, in China.
Read the full article on the original site.
Read Full Article